Dechra Pharmaceuticals PLC — AGM Information 2021

Oct 21, 2021

National Storage Mechanism | Additional information

RNS Number : 8263P

Dechra Pharmaceuticals PLC

21 October 2021

Thursday, 21 October 2021

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

A poll was held on each of the resolutions proposed at the Annual General Meeting (AGM) of the Company held today

(21 October 2021).  All resolutions were passed and are as follows:

Resolution (No. as noted on proxy form)	Total For (includes Discretionary)		Total Against		Total Cast (excludes Withheld)		Withheld (1)
	No. of votes	% of vote	No. of votes	% of vote	No. of votes	% of vote	No. of votes
Ordinary Business:
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report	79,448,606	99.82%	143,377	0.18%	79,591,983	73.48	663,610
Resolution 2: To approve the Directors' Remuneration Report	73,810,257	92.98%	5,568,679	7.02%	79,378,936	73.28	876,657
Resolution 3: To declare a final dividend	80,166,277	99.89%	89,166	0.11%	80,255,443	74.09	150
Resolution 4: To elect Denise Goode	79,625,037	99.22%	627,942	0.78%	80,252,979	74.09	2,614
Resolution 5: To re-elect William Anthony Rice	74,049,166	93.28%	5,335,791	6.72%	79,384,957	73.29	870,636
Resolution 6: To re-elect Ian Page	79,100,749	99.25%	600,742	0.75%	79,701,491	73.58	554,102
Resolution 7: To re-elect Anthony Griffin	79,676,525	99.28%	575,456	0.72%	80,251,981	74.09	3,612
Resolution 8: To re-elect Paul Sandland	79,610,115	99.20%	641,866	0.80%	80,251,981	74.09	3,612
Resolution 9: To re-elect Lisa Bright	78,905,240	98.32%	1,347,739	1.68%	80,252,979	74.09	2,614
Resolution 10: To re-elect Julian Heslop	78,904,870	98.32%	1,345,590	1.68%	80,250,460	74.09	5,133
Resolution 11: To re-elect Ishbel Macpherson	76,155,668	94.89%	4,097,310	5.11%	80,252,978	74.09	2,615
Resolution 12: To re-elect Lawson Macartney	78,909,123	98.33%	1,342,858	1.67%	80,251,981	74.09	3,612
Resolution 13: To re-elect Alison Platt	78,904,047	98.32%	1,348,932	1.68%	80,252,979	74.09	2,614
Resolution 14: To re-appoint PricewaterhouseCoopers as external auditor of the company	79,641,188	99.24%	611,253	0.76%	80,252,441	74.09	3,152
Resolution 15: To authorise the Audit Committee to determine the remuneration of the external auditor	80,202,414	99.94%	49,995	0.06%	80,252,409	74.09	3,184
Special Business:
Resolution 16: To authorise the directors to allot shares to specific limits	76,333,783	95.12%	3,919,660	4.88%	80,253,443	74.09	2,150
Resolution 17: To disapply the pre-emption rights	80,204,580	99.94%	45,655	0.06%	80,250,235	74.09	5,358
Resolution 18: To disapply additional pre-emption rights	78,534,264	97.86%	1,718,271	2.14%	80,252,535	74.09	3,058
Resolution 19: To authorise the Company to purchase its own shares	79,403,128	98.98%	818,816	1.02%	80,221,944	74.06	33,649
Resolution 20: To authorise the Company to hold any general meeting (other than an AGM) on not less than 14 clear days' notice	76,073,415	96.53%	2,734,994	3.47%	78,808,409	72.76	1,447,184
Resolution 21: To approve the Rules of the Dechra 2021 Deferred Bonus Plan	76,194,020	95.60%	3,507,352	4.40%	79,701,372	73.58	554,221

Notes:

1.       A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

2.       Resolutions 1 to 16 and Resolution 21 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

3.       Resolutions 17 to 20 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

4.       Issued Share Capital at meeting date: 108,319,960.

5.       Equiniti, Registrar to the Company, were appointed for the purpose of the Poll taken at the AGM and certify as scrutineer that the result of the Poll is correctly set out above.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

For further information, please contact:

Melanie Hall

Company Secretary

Dechra Pharmaceuticals PLC

Telephone: +44 (0) 1606 814 730

Email: corporate.enquiries@dechra.com 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFEMSUFEFSELS